^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

futuximab/modotuximab (S95026)

i
Other names: S95026, S095026, DS 992/DS 1024, DS-1024/DS-992, Sym004, S-095026, S-95026, S 095026, S 95026
Company:
Servier
Drug class:
EGFR inhibitor
Related drugs:
3ms
Trial completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
futuximab/modotuximab (S95026) • S95029 • Sym021
5ms
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma. (PubMed, Expert Opin Biol Ther)
Nivolumab and pembrolizumab are anti-PD-1 antibodies that improve immunosuppression by binding to programmed death-1 (PD-1), leading to an antitumor effect...Sym004 and amivantamab are antibodies that target the epidermal growth factor receptor and have demonstrated efficacy in the treatment of other tumors in recent phase I studies. Furthermore, clinical trials on antibody-drug conjugates such as enfortumab vedotin and DS-7300 for solid tumors are currently ongoing. The standard first-line treatments for patients with advanced ESCC contain ICIs. Therefore, drugs with different mechanisms of action that can overcome resistance to ICIs are needed as second-line or later-line treatments to improve clinical outcomes in these patients.
Review • Journal • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Rybrevant (amivantamab-vmjw) • Padcev (enfortumab vedotin-ejfv) • ifinatamab deruxtecan (DS-7300) • futuximab/modotuximab (S95026)
7ms
Trial completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
|
futuximab/modotuximab (S95026) • S95029 • Sym021
9ms
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
|
futuximab/modotuximab (S95026) • S95029 • Sym021
11ms
Phase classification • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
|
futuximab/modotuximab (S95026) • S95029 • Sym021
1year
COLSTAR: Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov)
P3, N=7, Terminated, Institut de Recherches Internationales Servier | N=500 --> 7 | Trial completion date: Oct 2026 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jun 2023; Decision based on strategic reasons related to limited development options left in metastatic colorectal cancer.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type
|
Lonsurf (trifluridine/tipiracil) • futuximab/modotuximab (S95026)
over1year
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)
P1a/1b, N=39, Recruiting, Institut de Recherches Internationales Servier | N=129 --> 39 | Trial completion date: Jul 2025 --> Jan 2024 | Trial primary completion date: May 2023 --> Jan 2024
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
|
futuximab/modotuximab (S95026) • S95029 • Sym021
over1year
COLSTAR study: Safety data on the first cohort of patients from the safety lead-in part of the study (ESMO-GI 2023)
Funding: The study was funded by Institut de Recherches Internationales Servier.Background: Futuximab/modotuximab (Fu/Mo) is a mixture of two monoclonal antibodies that binds to non-overlapping epitopes of the extracellular domain of the anti-epidermal growth factor receptor (EGFR)...Following the results of a phase 2 trial with Fu/Mo in RASwt mCRC, a phase 3 study in combination with trifluridine/tipiracil (TT) was planned with a safety lead-in part to demonstrate the tolerability of the combination. Here we report the results of the first 7 included patients. COLSTAR is a randomized, open-label study comparing Fu/Mo combined with TT to TT monotherapy in RAS/BRAFwt mCRC patients previously treated with chemotherapy (including oxaliplatin, irinotecan, 5-fluorouracil, anti-VEGF and anti-EGFR)... Overall, the combination of Fu/Mo with TT was well tolerated in this cohort of 7 patients and no new safety signals were observed.
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF wild-type
|
Guardant360® CDx
|
5-fluorouracil • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • futuximab/modotuximab (S95026)
over2years
COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment (ESMO 2022)
Main eligibility criteria include KRAS/NRAS (exons 2, 3 and 4) and BRAF wt (V600E mutation) (double negative; DN) assessed by centralized analysis of ctDNA at screening, and previous treatment with at least 2 regimens including fluoropyrimidine, irinotecan, oxaliplatin, at least one anti-VEGF (bevacizumab, aflibercept, ramucirumab, regorafenib) and at least one anti-EGFR mAb (cetuximab or panitumumab) for ≥4 months. The key secondary endpoint is OS in the triple-negative (KRAS/NRAS, BRAF, and EGFR-ECD wt) population (part 2). A group sequential design with 3 interim analyses (IA) will allow to stop the trial prematurely for futility at each IA as well as for efficacy at last IA.
Clinical • P3 data
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)
|
BRAF V600E • KRAS wild-type • BRAF wild-type • NRAS wild-type • KRAS exon 2 mutation • BRAF V600 wild-type • BRAF wild-type + NRAS wild-type
|
Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab) • Stivarga (regorafenib) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • futuximab/modotuximab (S95026)
over2years
Enrollment open • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type
|
Lonsurf (trifluridine/tipiracil) • futuximab/modotuximab (S95026)
almost3years
New P3 trial • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type
|
Lonsurf (trifluridine/tipiracil) • futuximab/modotuximab (S95026)
almost3years
Clinical • New P1 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
|
futuximab/modotuximab (S95026) • Sym021
almost4years
Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation. (PubMed, Sci Rep)
Consistently Sym004 efficacy and potentiation of cisplatin responses correlated with EGFR surface expression in head and neck cancer cells. These findings will have implications in understanding the mode of action of this new class of cancer therapeutics.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression
|
cisplatin • futuximab/modotuximab (S95026)
over4years
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
P2, N=43, Completed, Annick Desjardins | Active, not recruiting --> Completed | Trial completion date: Aug 2021 --> Apr 2020
Clinical • Trial completion • Trial completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR amplification
|
futuximab/modotuximab (S95026)